TrialJNCI cancer spectrum2021

Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis.

Marco A J Iafolla et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.